LivaNova publishes 24-month data from CORE-VNS study in Epilepsia

LivaNova (LIVN) announced that 24-month data on generalized tonic-clonic seizures in people with drug-resistant epilepsy from the CORE-VNS three-year study have been published in Epilepsia. Several CORE-VNS study findings were highlighted in the recent article on GTC seizures in DRE patients who received VNS Therapy, including: at 12 months, the median reduction in GTC seizure frequency was 74%, and this reduction was sustained through 24 months with a median reduction increasing to 77%; freedom from GTC seizures was reported by 37% and 43% of people at the 12- and 24-month study visits, respectively, despite people having a median 10-year duration of epilepsy; approximately half of those experiencing GTC seizures were under 18 years of age, and nearly all had no history of any other previous surgery for epilepsy. GTC seizure reduction was seen early, with a median 52% reduction in GTC seizure frequency at the three-month study visit. CORE-VNS participants have been followed through the 36-month study interval, and LivaNova is currently in the process of publishing 36-month study outcomes.